All news

Pulse Biosciences slips ahead of Oppenheimer management meeting

Alpha Vantage · AD HOC NEWS · · AI-summarised by FinFlash

Pulse Biosciences shares fell 3.87% to USD 47.90 ahead of a management meeting with Oppenheimer in San Francisco on October 7-8, 2026. The company posted Q2 2026 revenue of USD 434,000 and an adjusted loss of USD 0.36 per share, missing consensus estimates. Analysts keep a "Moderate Buy" rating with an average price target of USD 50.20, citing the need for regulatory progress and market adoption of its Nano-Pulse Stimulation technology.

Read original source

PLSE company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.